
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a ...
Dr. Hasskarl to lead global Phase 3 MO-TRANS study evaluating mocravimod as an adjunctive treatment to allo-HCT in AML Saint-Louis, France and Dublin, Ireland – 6th May 2025– Priothera Ltd., a late-stage biopharma company pioneering the development of …